1
|
Monfardini S, Brunello A, Molino A, Sacco C, Simoncini E, Gasparini G, Bella MA, Crivellari D, Vamvakas L, Basso U. Comorbidity and choice of adjuvant endocrine therapy in breast cancer patients (pts) older than 70 years. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8546] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8546 Background: Tamoxifen (Tam) and aromatase inhibitors (AI) have different profiles of toxicity which may influence the therapeutic choice in the presence of associated diseases, but few data are available concerning the prevalence of such comorbidities. Methods: A retrospective analysis on 434 consecutive pts (≥70 years) radically operated for breast cancer was conducted in 26 italian centers to determine how comorbidity influenced the choice of endocrine therapy during the year 2004. Results: Out of 434 pts, 367 with estrogen receptor positivity (median age 75, range 70–93) were treated with endocrine therapy alone (330 pts) or combined with chemotherapy (37 pts). The mean number of comorbidities was 1.8; 99 pts (26.2%) had ≥3 associated diseases. Tam was given to 194 pts (52,8%), AI to 173 pts (47,2%): Anastrozole (149 pts) Letrozole (22 pts) or Exemestane (2 pts). In 126/367 pts (34%) AI were prescribed instead of Tam because of the contraindications listed in the table below. AI were the preferred choice in 46/367 (12,5 %) pts in the absence of contraindications to Tam. Whereas the prevalence of osteoporosis is more than 30% in women after 70 years in Italy, a reduction of bone density had been instrumentally documented only in 10 pts (2.7%) of this survey, and AI were prescribed in 6 of them. Conclusions: Tam was still the preferred option in elderly women with early breast cancer, but was contraindicated in more than one third of pts. These data suggest that osteoporosis is being probably underdiagnosed in patients over 70 years. In view of a possible treatment with bisphosphonates, screening bone mineralometry should become standard before starting therapy with AI. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Monfardini
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - A. Brunello
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - A. Molino
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - C. Sacco
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - E. Simoncini
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - G. Gasparini
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - M. A. Bella
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - D. Crivellari
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - L. Vamvakas
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| | - U. Basso
- Istituto Oncologico Veneto, Padova, Italy; University Hospital, Verona, Italy; University Hospital, Udine, Italy; Spedali Civili, Brescia, Italy; San Filippo Neri Hospital, Roma, Italy; Azienda Ospedaliera, Parma, Italy; CRO, Aviano, Italy; University General Hospital, Heraklion, Greece
| |
Collapse
|
2
|
Cocconi G, Di Blasio B, Boni C, Bisagni G, Rondini E, Bella MA, Leonardi F, Savoldi L, Vallisneri C, Camisa R, Bruzzi P. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes. Ann Oncol 2005; 16:1469-76. [PMID: 15956038 DOI: 10.1093/annonc/mdi278] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The role of anthracyclines has been extensively studied in adjuvant chemotherapy, but much less in the primary chemotherapy of early breast carcinoma. This study, comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with the rotational anthracycline-containing regimen CMFEV (CMF plus epirubicin and vincristine) administered as primary chemotherapy, demonstrated a significant increase in clinical complete response in premenopausal women. We report the long-term results. PATIENTS AND METHODS Two hundred and eleven patients with stage I or II palpable breast carcinoma and a tumour diameter of >2.5 cm were randomised to receive CMF or CMFEV for four cycles before surgery. After surgery, the patients in both arms received adjuvant CMF for three cycles. RESULTS In the study population as a whole, there was a non-significant 20% reduction in mortality and relapse rates in the CMFEV arm. However, the effect of the experimental regimen was only found in premenopausal patients, especially in terms of relapse-free survival (P=0.07) and locoregional relapse-free survival (P=0.0009), thus mirroring the effect on response rates. After 10 years, the proportions of premenopausal patients free from locoregional relapse as a first event in the CMF and CMFEV groups were 68% and 97%, respectively. No relevant differences were found in postmenopausal patients. CONCLUSION The overall results of this study showed that the greater activity of the experimental anthracycline-containing combination over CMF as primary chemotherapy in premenopausal patients translated into long-term effects in the same subgroup.
Collapse
Affiliation(s)
- G Cocconi
- Medical Oncology Division, Azienda Ospedaliera Universitaria of Parma, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Musolino A, Bella MA, Michiara M, Zanelli P, Naldi N, Bortesi B, Capelletti M, Bandini N, Camisa R, Franciosi V. BRCA1 status, molecular markers, clinical variables in breast cancer patients with high probability of having an inherited genetic mutation. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Musolino
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - M. A. Bella
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - M. Michiara
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - P. Zanelli
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - N. Naldi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - B. Bortesi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - M. Capelletti
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - N. Bandini
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - R. Camisa
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - V. Franciosi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| |
Collapse
|
4
|
Michiara M, Bella MA, Naldi N, Musolino A, Zanelli P, Bortesi B, Capelletti M, De Lisi V, Sgargi P, Franciosi V. Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Michiara
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - M. A. Bella
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - N. Naldi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - A. Musolino
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - P. Zanelli
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - B. Bortesi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - M. Capelletti
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - V. De Lisi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - P. Sgargi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| | - V. Franciosi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy; Parma Cancer Registry, Parma, Italy
| |
Collapse
|
5
|
Bella MA, Michiara M, Musolino A, Naldi N, Zanelli P, Bortesi B, Capelletti M, Bandini N, Franciosi V. Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. A. Bella
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - M. Michiara
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - A. Musolino
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - N. Naldi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - P. Zanelli
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - B. Bortesi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - M. Capelletti
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - N. Bandini
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| | - V. Franciosi
- Medical Oncology Unit, University Hospital, Parma, Italy; Medical Genetic Service, University Hospital, Parma, Italy
| |
Collapse
|
6
|
Cocconi G, Mambrini A, Quarta M, Vasini G, Bella MA, Ferrozzi F, Beretta MD. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma. Cancer 2000; 88:2731-8. [PMID: 10870055 DOI: 10.1002/1097-0142(20000615)88:12<2731::aid-cncr11>3.0.co;2-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Vinorelbine (VI) and paclitaxel (TA) are among the most active single agents in the treatment of patients with breast carcinoma, and both have microtubules as their cytotoxic target. This Phase I-II study combined these 2 agents and used a 96-hour intravenous (i.v.) infusion of paclitaxel to maximize their cytotoxic activities. METHODS Patients with metastatic breast carcinoma who were previously treated with chemotherapy were administered increasing doses of a 96-hour paclitaxel i.v. infusion from Days 1 to 5, with a first fixed dose of vinorelbine (12.5 mg/m(2) on Days 1 and 5) every 3 weeks. The dose of paclitaxel was then decreased starting from the previously established tolerated dose, and a second fixed dose of vinorelbine (15 mg/m(2) on Days 1 and 5) was given. This identified 2 acceptable doses of paclitaxel (110 mg/m(2) with VI 12.5 mg/m(2) and 90 mg/m(2) with VI 15 mg/m(2)). The latter was used in the subsequent Phase II study. RESULTS For the 50 patients treated with any dose, the complete response (CR) and the CR plus partial response (PR) rates were, respectively, 14% and 48% (95% confidence interval [CI], 34-67%). When only the 27 patients treated with the Phase II dose were considered, the figures were, respectively, 11% and 52% (95% CI, 42-62%). The median time to progression was 26 weeks, and the median survival 51 weeks. The dose-limiting toxicity was febrile neutropenia. CONCLUSIONS At the dose schedule identified for the Phase II study, the VI-TA-96 combination has considerable antitumor activity; pharmacoeconomic interest (it requires about half the doses of the agents administered singly); no major toxicity, except G4 neutropenia; and no need for premedication. This combination may be recommended as one of the most effective therapeutic options for patients with metastatic breast carcinoma who were pretreated mainly with anthracycline-containing chemotherapy.
Collapse
Affiliation(s)
- G Cocconi
- Medical Oncology Division, University Hospital, Parma, Italy
| | | | | | | | | | | | | |
Collapse
|
7
|
Bozzetti C, Nizzoli R, Naldi N, Guazzi A, Camisa R, Bella MA, Cocconi G. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors. Cancer 1999; 87:224-30. [PMID: 10455211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
BACKGROUND The bcl-2 gene encodes for a protein that is involved in cell death regulation. It frequently is expressed in breast tumors, in which it is associated with favorable prognostic factors. It has been suggested that bcl-2 also may act as a modulator of response to chemotherapy and/or endocrine therapy. Because fine-needle aspiration (FNA) biopsy has been established as a reliable method for the diagnosis and biologic characterization of breast carcinoma, we assessed Bcl-2 expression on FNAs from primary breast carcinoma and evaluated its correlations with other prognostic variables. METHODS Bcl-2, estrogen receptor (ER), progesterone receptor (PgR), p53 protein expression, and Ki-67 growth fraction were evaluated by immunocytochemistry on FNAs from 130 patients with primary breast carcinoma. Nuclear cytologic grade was assessed on FNA smears. RESULTS Bcl-2 was expressed in 99 of 130 FNAs (76%). Bcl-2 expression was correlated with positive ER (P < 0.001) and PgR (P < 0.001) status and inversely correlated with p53 (P = 0.0036), Ki-67 (P = 0.0073), and nuclear cytologic grade (P < 0.001). CONCLUSIONS Bcl-2 expression, evaluated by immunocytochemistry on FNAs from primary breast carcinoma, correlates with favorable prognostic features such as ER and PgR expression, p53 negativity, a low Ki-67 index, and high tumor differentiation. These results are in agreement with those found on histologic samples. As FNA biopsy is used increasingly as a primary tool in the diagnosis of breast carcinoma, Bcl-2 evaluation by immunocytochemistry on FNA may provide, in addition to other biologic variables, useful information for prognostic and predictive purposes, particularly in patients considered to be candidates for neoadjuvant treatments. Cancer (Cancer Cytopathol)
Collapse
Affiliation(s)
- C Bozzetti
- Divisione di Oncologia Medica, Ospedale di Parma, Parma, Italy
| | | | | | | | | | | | | |
Collapse
|
8
|
Passalacqua R, Cocconi G, Caminiti C, Silingardi V, Bella MA, Bichisao E, Michiara M, Malavasi V, Donati D, Di Costanzo F, Rocca A, Di Sarra S, Scaglione F, Fraschini F. Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer. J Clin Oncol 1997; 15:2467-73. [PMID: 9196163 DOI: 10.1200/jco.1997.15.6.2467] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE To compare, in a double-blind, placebo-controlled, randomized trial, the efficacy of two different doses of the depot formulation of adrenocorticotropic hormone (ACTH) in controlling delayed emesis after cisplatin. PATIENTS AND METHODS One hundred fifty-two patients were enrolled onto the study. On day 1, all patients received cisplatin (60 to 120 mg/m2) and a combination of dexamethasone 20 mg plus ondansetron or metoclopramide to prevent acute emesis. On day 2 (24 hours after cisplatin administration), patients were randomized to receive placebo, or ACTH 1 mg intramuscularly (I.M.), or ACTH 2 mg I.M. plus one additional dose of 1 mg on day 4. Details of vomiting, nausea, and adverse effects were recorded daily for every 24-hour period from day 2 to day 6. In a subset of patients, serum cortisol levels were measured between 20 and 72 hours after cisplatin administration. RESULTS One hundred fifty patients were assessable. Over the 5 days of the study, delayed vomiting occurred less frequently in the patients treated with ACTH 2 mg plus 1 mg than in those treated with ACTH 1 mg or placebo (28%, 38%, and 65%, respectively; P = .001). The greatest observed differences were seen on days 2 (24 to 48 hours; P = .01) and 3 (48 to 72 hours; P = .01). On days 4, 5, and 6 (96 to 144 hours), no significant differences were observed among the three arms. The severity of delayed emesis expressed as the mean number of emetic episodes per day was 0.48, 0.70, and 0.80, respectively (P = .002). Patients treated with the higher dose of ACTH had the least nausea on day 3 (P = .02) and day 4 (P = .03). Adrenal cortisol secretion rapidly increased after ACTH injection, but was suppressed for approximately 44 hours in the placebo group. Toxicity was mild and transient in all groups. CONCLUSION ACTH reduces the incidence and severity of delayed vomiting and nausea after cisplatin. A dose of 2 mg 24 hours after cisplatin is better than one of 1 mg. Whether the activity of ACTH is mediated only by adrenal corticosteroids needs to be verified.
Collapse
|
9
|
Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9:675-8. [PMID: 1829757 DOI: 10.1200/jco.1991.9.4.675] [Citation(s) in RCA: 208] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Ondansetron (OND) is a new 5-HT3 receptor antagonist that give complete protection from emesis/nausea in approximately 50% of cisplatin (CDDP)-treated patients. To evaluate if dexamethasone (DEX) added to OND increases antiemetic efficacy, we carried out a double-blind randomized crossover study to compare the antiemetic activity of OND with OND plus DEX. One hundred two chemotherapy-naive patients (44 women and 58 men) scheduled to receive CDDP chemotherapy at doses greater than or equal to 50 mg/m2 entered the study. Eighty-nine patients completed both cycles with the following results: complete protection from emesis/nausea was obtained in 57/59 patients (64.0%/66.3%) with OND and in 81/79 (91.0%/88.8%) with OND plus DEX (P = .0005/P = .0021). At the end of the study, 53% of the patients expressed a treatment preference, and of these, 74% chose OND plus DEX compared with 26% who preferred OND alone, a statistically significant difference (P less than .003). Side effects were very mild and not significantly different between the two treatments. We conclude that OND plus DEX is more efficacious than OND in protecting patients from CDDP-induced emesis and nausea.
Collapse
Affiliation(s)
- F Roila
- Division of Medical Oncology, Regional Hospital, Perugia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Hassan KM, Ali FE, Bella MA. Cryptosporidiosis among children attending the Maternity and Paediatrics Teaching Hospital, Wad Medani, Central Region, Sudan. J Egypt Soc Parasitol 1991; 21:213-8. [PMID: 2033293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Modified Ziehl Neelson staining technique was used to identify Cryptosporidium species oocysts in stool specimens. Faecal samples from 166 children with diarrhoea and from a control of 95 children, were submitted for examination. 13 children from among those with diarrhoea and none from the control group were found to have Cryptosporidium species oocysts. The majority of these 13 positive children presented with abdominal pain, nausea, low grade fever and anorexia.
Collapse
Affiliation(s)
- K M Hassan
- Department of Pathology, Faculty of Medicine, University of Gezira, Sudan
| | | | | |
Collapse
|